MedDataX Logo

Endothelial Cell Specific Molecule-1 (ESM-1): a Novel Biomarker for ARDS Endothelial Injury

NCT ID: NCT03296761

Last Updated: 2017-11-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

70 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-11-01

Study Completion Date

2018-02-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To observe the changes of plasma ESM-1 levels in patients with ARDS, and to explore its clinical significance.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

70 patients who diagnosed as ARDS were included in this study. Then keep blood samples from these patients in the first day, the third day and the seventh day, detect ESM-1 level in plasma by ELISA. Record Severity of illness and survival status of every patient within 28 days. Objective to evaluate the correlation between the level of ESM-1 in plasma and the prognosis of the patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Evaluate the Correlation Between the Level of ESM-1 and the Prognosis of the Patients With ARDS

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ESM-1<5ng/ml

No interventions assigned to this group

ESM-1≥5ng/ml

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients admitted to ICU diagnosed of ARDS (Berlin definition）in 48h
2. Patients age between 18 years old and 80 years.

Exclusion Criteria

1. Pregnant women,
2. Patients with malignant tumor,
3. Immunosuppression or immunocompromised patients.
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Jingyuan,Xu

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jingyuan,Xu

chief doctor

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Haibo qiu

Role: STUDY_CHAIR

Zhong-Da Hospital, School of Medicine, Southeast University,

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Nanjing Zhongda Hospital, School of Medicine, Southeast University

Nanjing, Jiangsu, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Yuanyuan YU

Role: CONTACT

Phone: 15651680953

Email: [email protected]

Haibo qiu

Role: CONTACT

Phone: +862583262550

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Yuanyuan YU

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2017ZDSYLL081-P01

Identifier Type: -

Identifier Source: org_study_id